EZH2 and gastric cancer: Additionally, increased sensitivity of ARID1A-deficient cancer cells to treatment with small molecule inhibitor of the PI3K/AKT pathway or selective sensitivity of EZH2 inhibitors against ARID1A-deficient gastric cancer could be demonstrated [41,42,43].